Devyser, a company focused on diagnostic solutions and analysis services for clinical laboratories, announced on Wednesday that it has signed a collaboration agreement with US-based Thermo Fisher Scientific for promoting laboratory services.

The aim is to collaborate with pharmaceutical companies to support their development projects using Devyser's unique assays in its CLIA-certified laboratory. Both firms are to collaborate to promote the Devyser laboratory services to support and progress research and development for pharmaceutical companies.

Fredrik Alpsten, CEO at Devyser, said, 'We are very excited to enter into this agreement. Being able to support pharmaceutical companies' development projects to enable new and improved therapies is a part of our vision for Devyser. We are convinced that Thermo Fisher, with its global network and outstanding reach, will provide a strong platform for partnering with global pharmaceutical companies in addition to Devyser's own discussions. This collaboration is in line with our strategy to expand our presence in the US.'